Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares

Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.